The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy

GC Nguyen, CH Seow, C Maxwell, V Huang, Y Leung… - Gastroenterology, 2016 - Elsevier
Background & Aims The management of inflammatory bowel disease (IBD) poses a
particular challenge during pregnancy because the health of both the mother and the fetus …

Immunogenicity of biologics in chronic inflammatory diseases: a systematic review

V Strand, A Balsa, J Al-Saleh, L Barile-Fabris… - BioDrugs, 2017 - Springer
Objectives A systematic review was conducted to explore the immunogenicity of biologic
agents across inflammatory diseases and its potential impact on efficacy/safety. Methods …

The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update

PF Van Rheenen, M Aloi, A Assa… - Journal of Crohn's …, 2021 - academic.oup.com
Objective We aimed to provide an evidence-supported update of the ECCO-ESPGHAN
guideline on the medical management of paediatric Crohn's disease [CD]. Methods We …

ECCO guidelines on therapeutics in Crohn's disease: medical treatment

J Torres, S Bonovas, G Doherty… - Journal of Crohn's …, 2020 - academic.oup.com
2. Methods Based on the GRADE workflow, the Guidelines Committee of ECCO [GuiCom]
selected a panel of 48 experts supported by a team of methodologists and librarians …

Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management

M Harbord, R Eliakim, D Bettenworth… - Journal of Crohn's …, 2017 - academic.oup.com
11.1. General The treatment strategy for ulcerative colitis [UC] is mainly based on the
severity, distribution [proctitis, left-sided, extensive] 1 and pattern of disease. The latter …

ECCO guidelines on therapeutics in Crohn's disease: surgical treatment

M Adamina, S Minozzi, J Warusavitarne… - Journal of Crohn's …, 2024 - academic.oup.com
This article is the second in a series of two publications on the European Crohn's and Colitis
Organisation [ECCO] evidence-based consensus on the management of Crohn's disease …

Loss of response to anti-TNFs: definition, epidemiology, and management

G Roda, B Jharap, N Neeraj… - Clinical and translational …, 2016 - journals.lww.com
Tumor necrosis factor-α (TNFα) antagonists have advanced the management of
inflammatory bowel diseases patients leading to an improvement of patient's quality of life …

Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease

NV Casteele, M Ferrante, G Van Assche, V Ballet… - Gastroenterology, 2015 - Elsevier
Background & Aims Infliximab, a tumor necrosis factor antagonist, is effective for treating
patients with Crohn's disease (CD) and ulcerative colitis (UC). We aimed to determine …

Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease

FM Ruemmele, G Veres, KL Kolho… - Journal of Crohn's …, 2014 - academic.oup.com
Children and adolescents with Crohn's disease (CD) present often with a more complicated
disease course compared to adult patients. In addition, the potential impact of CD on growth …

Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label …

E Louis, M Resche-Rigon, D Laharie… - The Lancet …, 2023 - thelancet.com
Background The combination of infliximab and immunosuppressant therapy is a standard
management strategy for patients with Crohn's disease. Concerns regarding the implications …